Alnylam Pharmaceuticals, Inc. ALNY, the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 9:00 am ET in New York City.
A live audio webcast of the presentation will be available on the Investors section of the company's website, www.alnylam.com. A replay will be available on the Alnylam website within 48 hours after each event.
About Alnylam Pharmaceuticals
Alnylam ALNY is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of patients who have limited or inadequate treatment options. Based on
Nobel Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a bold
vision to turn scientific possibility into reality, with a robust
discovery platform and deep pipeline of investigational medicines,
including three product candidates that are in late-stage development or
will be in 2017. Looking forward, Alnylam will continue to execute on
its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines. For more information about our people, science
and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170530005199/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.